



Contact:

Intact Medical Corporation

Christopher Bleck, President and CEO
508-655-7820

Rx Communications Group

Paula Schwartz (investors) 917-322-2216
Tony Ho Loke (media) 917-322-2164

INTACT MEDICAL CORPORATION APPOINTS DANIEL J. BENEY
VICE PRESIDENT OF SALES

NATICK, MA, JANUARY 4, 2006 – Intact Medical Corporation, an emerging leader in the development and marketing of minimally invasive systems for the diagnosis of breast cancer, today announced that, effective January 2, 2006, Daniel J. Beney has been appointed to the position of Vice President of Sales. In this position, Mr. Beney will report directly to Christopher Bleck, President and Chief Executive Officer. Reporting to Mr. Beney at Intact Medical Corporation will be the Intact Medical Sales Team, comprised of a national organization of Area Sales Directors.

Commenting on today's news, Mr. Bleck noted, "We are pleased to welcome Dan to Intact Medical Corporation. As one of the original members of the Biopsys sales team, Dan helped pave the way for the advent of vacuum-assisted core biopsy and the replacement of fine needle aspiration as the standard of care in breast biopsy. Today, Dan shares our vision that our *Intact* Breast Lesion Excision System (BLES) can further advance the field of breast biopsy, providing complete excisions of breast lesions and potentially avoiding unnecessary surgical biopsy on benign lesions. His expertise in women's health and breast biopsy will be invaluable to the Company as we continue to ramp up our sales and marketing efforts for the *Intact*[™] Breast Lesion Excision System."

Mr. Beney has over 20 years of extensive sales experience in the medical device industry, including women's health. From 2002 until joining Intact Medical Corporation, he served as Director of Sales, Eastern Area, for Conceptus, Inc., a manufacturer and marketer of the Essure Permanent Birth Control system, a medical device and procedure designed to provide a non-incisional alternative to tubal



ligation. While with Conceptus, Mr. Beney was responsible for market development and the management of seven regional sales representatives.

Prior to Conceptus, Mr. Beney was Co-Founder of Simplicity Medical Systems, Inc., a development stage company specializing in the development and distribution of image-guided biopsy systems used in minimally invasive procedures, including those performed by specialists in breast related diseases. Before that, from 1999 to 2001, Mr. Beney was Vice President of Sales for Neurometrix, Inc., a development stage medical device company that manufactures and distributes non-invasive neuromuscular diagnostic equipment. At Neurometrix, Mr. Beney managed a multi-million dollar budget and an 18 member sales team.

From 1995 to 1999, Mr. Beney was with Ethicon Endosurgery Breast Care, which focused on the development, marketing and sales of devices for the early detection and diagnosis of breast cancer, ultimately serving as National Sales Manager for the company. In that position, Mr. Beney was responsible for integrating the sales organization of a recent acquisition, as well as formation and management of a 60 person sales team and \$15 million budget. While there, Mr. Beney successfully increased sales from \$22 million in 1997 to \$41 million in 1998. Mr. Beney's professional experience also includes various sales positions with Scimed Life Systems and Alcon Surgical.

Mr. Beney resides in Newton, MA and earned his Bachelor of Arts degree in Advertising from Michigan State University.

About Intact Medical Corporation

Founded in 1998, and based in Natick, Massachusetts, Intact Medical Corporation is a privately held company focused on the design, development and marketing of innovative, minimally invasive systems for the volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets. The Company's lead product, the *Intact*[™] Breast Lesion Excision System, received market clearance from the Food and Drug Administration in June 2001. Initial products are targeted at breast biopsy and the excision of benign lesions, potentially obviating the need for open surgical excisions. In August 2005, the company received expanded approval for the System, allowing its use



to obtain tissue samples for histologic examination with partial or complete removal of an imaged abnormality, or partial removal of a palpable abnormality that has been classified as benign.

For more information on Intact Medical Corporation, visit www.intactmedical.com

###